Literature DB >> 9792032

Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis.

M J Arthur1, D A Mann, J P Iredale.   

Abstract

Hepatic stellate cells (HSC) play a central role in the pathogenesis of liver fibrosis. Following liver injury, these cells proliferate and are activated to a profibrogenic myofibroblastic phenotype. In addition to increased matrix protein synthesis, there is evidence to indicate that these cells are able to regulate matrix degradation. In the early phases of their cellular activation, HSC release matrix metalloproteinases with the ability to degrade the normal liver matrix. When HSC are fully activated, there is a net down-regulation of matrix degradation mediated by increased synthesis and extracellular release of tissue inhibitors of metalloproteinase (TIMP)-1 and -2. These studies in cell culture have been complemented by in vivo studies of hepatic TIMP-1 and TIMP-2 gene expression. In advanced human liver disease of various aetiologies, there is increased TIMP-1-mRNA and protein and increased TIMP-2-mRNA in fibrotic liver compared with control liver. Temporal studies of progressive rat liver fibrosis caused by bile duct ligation or by carbon tetrachloride, indicate an important role for increased TIMP-1 and TIMP-2 expression in pathogenesis. Moreover, in a rat model of reversible liver fibrosis, matrix remodelling and resolution of liver fibrosis is closely associated, temporally, with a marked decrease in TIMP-1 and TIMP-2 expression. These combined cell culture and in vivo findings have led us to investigate the mechanisms of regulation of TIMP-1 gene expression in hepatic stellate cells. Our recent data indicate that transcriptional regulation of TIMP-1 gene expression in HSC is mediated via a mechanism which differs considerably from that previously identified in skin fibroblasts. We conclude that increased TIMP-1 and TIMP-2 expression by HSC plays an important role in the pathogenesis of liver fibrosis. This may represent an important therapeutic target in the design of anti-fibrotic strategies for chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792032

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  33 in total

1.  Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver.

Authors:  Hai-Lin Liu; Xuan-Hai Li; Dan-Yi Wang; Shao-Ping Yang
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

Review 2.  Transcriptional regulation of hepatic stellate cell activation.

Authors:  D A Mann; D E Smart
Journal:  Gut       Date:  2002-06       Impact factor: 23.059

3.  Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis.

Authors:  Q H Nie; Y Q Cheng; Y M Xie; Y X Zhou; Y Z Cao
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  Evaluation of hyaluronic acid, procollagen type III N-terminal peptide, and tissue inhibitor of matrix metalloproteinase-1 as serum markers of canine hepatic fibrosis.

Authors:  Jonathan A Lidbury; Aline Rodrigues Hoffmann; Joanna K Fry; Jan S Suchodolski; Jörg M Steiner
Journal:  Can J Vet Res       Date:  2016-10       Impact factor: 1.310

5.  Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model.

Authors:  Toshiaki Okamoto; Masahiko Koda; Kennichi Miyoshi; Takumi Onoyama; Manabu Kishina; Tomomitsu Matono; Takaaki Sugihara; Keiko Hosho; Junichi Okano; Hajime Isomoto; Yoshikazu Murawaki
Journal:  World J Hepatol       Date:  2016-08-08

6.  Impact of Hepatitis C Virus/Schistosoma mansoni Coinfection on the Circulating Levels of HCV-NS4 Protein and Extracellular-Matrix Deposition in Patients with Different Hepatic Fibrosis Stages.

Authors:  Abdelfattah M Attallah; Sanaa O Abdallah; Mohamed S Albannan; Mohamed M Omran; Ahmed A Attallah; Khaled Farid
Journal:  Am J Trop Med Hyg       Date:  2016-08-15       Impact factor: 2.345

7.  Inhibition on the production of collagen type I, III of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid.

Authors:  Wen-Bin Liu; Chang-Qing Yang; Wei Jiang; Yi-Qing Wang; Jing-Sheng Guo; Bo-Ming He; Ji-Yao Wang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 8.  Oxidative and nitrosative stress and fibrogenic response.

Authors:  R Urtasun; L Conde de la Rosa; N Nieto
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

9.  Association of age-dependent liver injury and fibrosis with immune cell populations.

Authors:  Bradley H Collins; Zoie E Holzknecht; Kellie A Lynn; Gregory D Sempowski; Catherine C Smith; Songling Liu; William Parker; Don C Rockey
Journal:  Liver Int       Date:  2013-05-26       Impact factor: 5.828

10.  Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.

Authors:  H Yoshiji; S Kuriyama; J Yoshii; Y Ikenaka; R Noguchi; D J Hicklin; Y Wu; K Yanase; T Namisaki; M Yamazaki; H Tsujinoue; H Imazu; T Masaki; H Fukui
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.